POA Pharma Scandinavia AB, part of Galen Limited, is pleased to announce a significant strategic development that further advances our growth and presence across the Nordic region.

We have entered a new exclusive licence and supply agreement with our longstanding partner, Laboratorios Salvat, S.A. This agreement marks an important expansion of POA’s ENT portfolio in the Nordics and reinforces the strong collaborative relationship that has supported the success of both organisations for many years.

Commenting on the announcement, Dennise Broderick, President and Managing Director of POA Pharma and Galen, said:

“Our partnership with Salvat is built on trust, shared ambition, and a commitment to improving patient outcomes. This new agreement is a strategic milestone for our Nordic expansion and reflects the strength of our collaboration, as well as our dedication to working with partners who share our vision for long-term, sustainable growth.”

This milestone highlights POA’s continued investment in the Nordic market and our focus on broadening our portfolio across key therapeutic areas. Launch planning is now underway, with preparations progressing to bring this new addition to the Nordic ENT market in the next fiscal year.

Our long‑term partnership strategy and commitment to sustainable growth remain central to POA’s vision for the future. This latest development reinforces our ambition to deepen our regional footprint and continue delivering high‑quality, evidence‑based healthcare solutions across the Nordics.

We extend our sincere thanks to all colleagues and partners involved in bringing this agreement to completion. Your collaboration, expertise, and dedication continue to drive POA forward and position us strongly for the years ahead.